ES2728471T3 - Agente para prevenir o mejorar el deterioro de la función cerebral - Google Patents

Agente para prevenir o mejorar el deterioro de la función cerebral Download PDF

Info

Publication number
ES2728471T3
ES2728471T3 ES13851411T ES13851411T ES2728471T3 ES 2728471 T3 ES2728471 T3 ES 2728471T3 ES 13851411 T ES13851411 T ES 13851411T ES 13851411 T ES13851411 T ES 13851411T ES 2728471 T3 ES2728471 T3 ES 2728471T3
Authority
ES
Spain
Prior art keywords
salt
citrulline
glutathione
group
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13851411T
Other languages
English (en)
Spanish (es)
Inventor
Kota Kumagai
Masahiko Morita
Takahiro Hara
Kohji Fukunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Application granted granted Critical
Publication of ES2728471T3 publication Critical patent/ES2728471T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13851411T 2012-10-30 2013-10-30 Agente para prevenir o mejorar el deterioro de la función cerebral Active ES2728471T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012238541 2012-10-30
PCT/JP2013/080052 WO2014069666A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (1)

Publication Number Publication Date
ES2728471T3 true ES2728471T3 (es) 2019-10-24

Family

ID=50627558

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13851411T Active ES2728471T3 (es) 2012-10-30 2013-10-30 Agente para prevenir o mejorar el deterioro de la función cerebral

Country Status (8)

Country Link
US (1) US10369186B2 (enExample)
EP (1) EP2914257B1 (enExample)
JP (1) JP6170166B2 (enExample)
AU (1) AU2013339057B2 (enExample)
CA (1) CA2888791C (enExample)
ES (1) ES2728471T3 (enExample)
NZ (1) NZ706862A (enExample)
WO (1) WO2014069666A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110392A (en) * 1964-09-28 1968-04-18 Yamanouchi Pharma Co Ltd Composition containing glutathione and an amino acid or amino acids, and salts thereof
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
AU5939901A (en) * 2000-10-27 2002-05-06 Nitromed Inc Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2002333018B2 (en) * 2001-09-27 2006-08-31 The Mental Health Research Institute Of Victoria Modulation of physiological processes and agents useful for same
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP4137906B2 (ja) * 2005-03-30 2008-08-20 ピアス株式会社 セラミダーゼ阻害剤
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
US8597640B2 (en) 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
AU2008347177B2 (en) * 2008-01-04 2014-04-17 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
WO2009096505A1 (ja) * 2008-01-30 2009-08-06 Kyowa Hakko Bio Co., Ltd. 注意集中力向上剤
US9918951B2 (en) 2008-02-05 2018-03-20 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
JP2010126462A (ja) * 2008-11-26 2010-06-10 Mitsubishi Gas Chemical Co Inc 脳機能改善用組成物および該組成物を含有する機能性食品

Also Published As

Publication number Publication date
JP2015535240A (ja) 2015-12-10
EP2914257A1 (en) 2015-09-09
CA2888791A1 (en) 2014-05-08
US10369186B2 (en) 2019-08-06
NZ706862A (en) 2019-03-29
JP6170166B2 (ja) 2017-07-26
AU2013339057A1 (en) 2015-04-30
EP2914257B1 (en) 2019-04-03
AU2013339057B2 (en) 2018-08-30
EP2914257A4 (en) 2016-07-27
US20150265670A1 (en) 2015-09-24
CA2888791C (en) 2021-07-27
WO2014069666A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
US11738037B2 (en) Agent for preventing or improving decline in brain function
ES2861583T3 (es) Preparación oral de acción rápida que puede aumentar el nivel de arginina en sangre y que comprende citrulina y arginina
JP5085541B2 (ja) 疲労軽減剤
JP6193229B2 (ja) 血管内皮機能低下の予防または改善剤
ES2940822T3 (es) Agente elevador de la concentración de óxido nítrico
US20160296586A1 (en) Agent for preventing or ameliorating vascular endothelial malfunction
ES2346859T3 (es) Precursores del glutation para el tratamiento de trastornos neurosiquiatricos.
JP5931325B2 (ja) 注意集中力向上剤
EP2914257B1 (en) Agent for preventing or improving decline in brain function
US20170042962A1 (en) Agent for preventing or ameliorating vascular endothelial malfunction